Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by cpt2010on May 05, 2020 1:23pm
268 Views
Post# 30988625

Initiated at 72, added 70c, 63c. Target $1.2 post data.

Initiated at 72, added 70c, 63c. Target $1.2 post data.Here are my thoughts.

We will play around between 68-80c prior to data. in 3 -4 weeks, price will be at around 80c.

I expect a 40-50% gain post data.
In 1 week post data, I expect a secondary of shares where they will get around $35 m. I feel this will be seen as positive and price will rise to around $1.25 in the next 2 months.

Over $1 it muti year breakout, with no resistance. Also, over $1 will bring more institutions. I feel Antibes is still unknown and will soon be known in the medical field, provided the drug works, which I think it does.

After that, Nasdaq listing potential into end 2020. Partnership possibility but a buyout highly likely.
I see a $1b valuation before Phase 3 results.

Good luck to all...long for the longer term here. 
Bullboard Posts